Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-15

Amarin Corp PLC\UK (AMRN)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,540,366
Aaron Berg total, FY2025
67th
CEO pay percentile vs peers
11:1
CEO-to-median pay ratio
51.9%
Say-on-pay support, latest vote
Companies that benchmark against AMRN
2 companies name AMRN as a compensation peer

Each company listed discloses AMRN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMRN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Aaron Berg$725,667$332,326$1,391,250$493,975$588,300$0$8,848$3,540,366
President and Chief Executive Officer
Steven Ketchum687,490429,09691,462339,564364,61008,8481,921,070
Executive Vice President, President of Research and Development and Chief Scientific Officer
David Keenan452,685357,77591,462339,564301,341073,4781,616,306
Executive Vice President, Chief Operating Officer
Jonathan Provoost484,181186,00091,462339,564257,08503,9411,362,233
Executive Vice President, Chief Legal & Compliance Officer and Secretary
Peter Fishman400,000173,75060,686225,295169,30007,9391,036,970
Senior Vice President, Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Aaron Berg$3,540,366$3,277,385$2,448,149+262,981
Steven Ketchum1,921,0701,732,8272,350,567+188,243
David Keenan1,616,306
Jonathan Provoost1,362,233701,819659,264+660,414
Peter Fishman1,036,970606,000+430,970

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Paul CohenDirector2026-04-18A838CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18D438156,561CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18D403156,037CommonForm 4 ↗
Dividend-equivalent accruals2026-04-185,8667 insiders, 7 accrual rows
Kostas D. OdysseasDirector2026-04-18D403156,037CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18D403156,037CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A838CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A838CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A838CommonForm 4 ↗
Paul CohenDirector2026-04-18D403156,037CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18A838CommonForm 4 ↗
Keith L. HornDirector2026-04-18A838CommonForm 4 ↗
Keith L. HornDirector2026-04-18D403156,037CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18A838CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,25000Derivative, Class A CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,250CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26D3,1971652,271CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01D1,8871630,079CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,447CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,688CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,44700Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01D1,2061619,224CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,688CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01D1,9261630,700CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,688CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01D1,2641620,148CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 36 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Paul CohenDirector2026-04-18A838CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18D438156,561CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18D403156,037CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18D403156,037CommonForm 4 ↗
Keith L. HornDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Paul CohenDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A838CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A838CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18D403156,037CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A838CommonForm 4 ↗
Paul CohenDirector2026-04-18D403156,037CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18A838CommonForm 4 ↗
Keith L. HornDirector2026-04-18A838CommonForm 4 ↗
Keith L. HornDirector2026-04-18D403156,037CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18A838CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,25000Derivative, Class A CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,250CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26D3,1971652,271CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01D1,8871630,079CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,447CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,688CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,44700Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01D1,2061619,224CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,688CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01D1,9261630,700CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,688CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01D1,2641620,148CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Jonathan ProvoostOPTION2025-01-10663,860$339,564
Peter FishmanOPTION2025-01-10440,460225,295
Steven KetchumOPTION2025-01-10663,860339,564
Aaron BergOPTION2025-06-26750,000493,975
David KeenanOPTION2025-01-10663,860339,564
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Jonathan Provoost$0$0$339,5640.0%
Peter Fishman00225,2950.0%
Steven Ketchum00339,5640.0%
Aaron Berg00493,9750.0%
David Keenan00339,5640.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Aaron BergOption8,2203.66
Aaron BergOption174,1601.21
Steven KetchumOption663,8600.62
Jonathan ProvoostOption400,0000.75
Steven KetchumOption174,1601.21
D.Option84,2601.8
Steven KetchumOption84,2401.8
D.Option12,5001.45
Aaron BergOption84,2401.8
D.Option663,8600.62
Aaron BergOption750,0000.8
Jonathan ProvoostOption663,8600.62
D.Option174,1601.21
Steven KetchumOption8,2203.66
Peter FishmanOption440,4600.62
05

Incentive-plan design — the Compensation Discussion & Analysis

Amarin's philosophy in setting compensation policies for executive officers has two fundamental objectives: (1) to attract and retain a highly skilled team of executives and (2) to align our executives interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation to increases in shareholder value.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)
Independent consultantPearl Meyer
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1387,198,31780,807,44017,509,84051.9%Passed
20252025-05-1388,817,07336,111,6986,716,64471.09%Passed
20242024-04-18111,449,58828,688,1213,628,09879.53%Passed
20232023-07-21116,866,03435,233,5864,934,47176.84%Passed
20222022-06-2785,564,19845,523,02253,634,85065.27%Passed
20212021-06-14102,483,11338,858,7761,587,32272.51%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1351.9%a
20252025-05-1371.09%b
20242024-04-1879.53%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

c. Approved under the standard stated in the filing — “As a result, abstentions and broker non-votes will have no effect on the vote outcome.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)11 : 1
CEO total compensation$3,540,366
Median employee compensation$326,639
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Odysseas KostasIndependent · Board Chair · Nominating and Corporate Governance$73,577$0$0$0$73,577
Keith L. HornIndependent · Audit (Chair) · Remuneration71,90300071,903
Diane E. SullivanIndependent · Audit · Remuneration (Chair)68,84200068,842
Louis Sterling IIIIndependent · Audit · Nominating and Corporate Governance (Chair)67,53200067,532
Patrice BonfiglioIndependent · Audit · Remuneration63,08900063,089
Paul CohenIndependent · Nominating and Corporate Governance · Not standing for re-election · Departed during FY54,71100054,711
Oliver O'ConnorIndependent · Nominating and Corporate Governance · Not standing for re-election · Departed during FY32,88300032,883
Michael TorokIndependent · Remuneration · Newly elected31,18900031,189
Mark DiPaoloIndependent · Departed during FY21,43500021,435
Aaron D. BergEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$62,500
Annual equity retainer$175,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 11,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$485,161
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$485,161

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Amarin Corp PLC\UK names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Amarin Corp PLC\UK.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Evolus, Inc.2025David Moatazedi$775,000$3,886,569$1,296,697$429,000$6,412,214
2Amarin Corp PLC\UK2025Aaron Berg725,6671,391,250493,975588,3003,540,366
3Esperion Therapeutics, Inc.2025Sheldon Koenig770,8331,260,000847,929639,3753,535,512
4Heron Therapeutics, Inc.2025Craig Collard689,431946,2541,352,917517,1893,516,291

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Amarin Corp PLC\UK107.75%Options 75 · RSU 25not disclosedPearl Meyer
Esperion Therapeutics, Inc.110%not disclosednot disclosednot disclosed
Evolus, Inc.55%not disclosedNoRadford, an Aon Company
Heron Therapeutics, Inc.100%Options 67 · RSU 33not disclosedCompensia, Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Aaron BergDEF 14A2026-04-100001193125-26-151417Section “Summary Compensation Table” · page 52. As printed: 3,540,366. Filing ↗machine: r2 · c30 · span 991658–991667
2Section 01, Steven KetchumDEF 14A2026-04-100001193125-26-151417Section “Summary Compensation Table” · page 52. As printed: 1,921,070. Filing ↗machine: r10 · c30 · span 1073899–1073908
3Section 01, David KeenanDEF 14A2026-04-100001193125-26-151417Section “Summary Compensation Table” · page 52. As printed: 1,616,306. Filing ↗machine: t28 · r7 · c28 · span 1046569–1046578
4Section 01, Jonathan ProvoostDEF 14A2026-04-100001193125-26-151417Section “Summary Compensation Table” · page 52. As printed: 1,362,233. Filing ↗machine: r13 · c30 · span 1106923–1106932
5Section 01, Peter FishmanDEF 14A2026-04-100001193125-26-151417Section “Summary Compensation Table” · page 52. As printed: 1,036,970. Filing ↗machine: r5 · c30 · span 1024646–1024655
6Section 03, Jonathan Provoost OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t28 · r13 · c16 · span 1102785–1102792
7Section 03, Peter Fishman OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r3 · c15 · span 1159126–1159133
8Section 03, Steven Ketchum OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r5 · c15 · span 1171140–1171147
9Section 03, Aaron Berg OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r2 · c15 · span 1153126–1153133
10Section 03, David Keenan OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r4 · c15 · span 1165132–1165139
11Section 07, pay ratioDEF 14A2026-04-100001193125-26-151417Section “CEO Pay Ratio”. As printed: 11 : 1. Filing ↗machine: t37 · r2 · c3 · span 1838690–1838697
12Section 08, Odysseas KostasDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 73,577. Filing ↗machine: t46 · r6 · c3 · span 2179896–2179902
13Section 08, Keith L. HornDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 71,903. Filing ↗machine: t46 · r5 · c3 · span 2173916–2173922
14Section 08, Diane E. SullivanDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 68,842. Filing ↗machine: t46 · r9 · c3 · span 2198001–2198007
15Section 08, Louis Sterling IIIDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 67,532. Filing ↗machine: t46 · r8 · c3 · span 2192019–2192025
16Section 08, Patrice BonfiglioDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 63,089. Filing ↗machine: t46 · r2 · c3 · span 2155666–2155672
17Section 08, Paul CohenDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 54,711. Filing ↗machine: t46 · r3 · c3 · span 2161801–2161807
18Section 08, Oliver O'ConnorDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 32,883. Filing ↗machine: t46 · r7 · c3 · span 2186036–2186042
19Section 08, Michael TorokDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 31,189. Filing ↗machine: t46 · r10 · c3 · span 2204139–2204145
20Section 08, Mark DiPaoloDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 21,435. Filing ↗machine: t46 · r4 · c3 · span 2167938–2167944
21Section 08, Aaron D. BergDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
58Section 06, 2026 voteForm 8-K2026-05-150001193125-26-224771Item 5.07 · say-on-pay result. As reported: 51.9% (votes for as printed: 87,198,317). Filing ↗
59Section 06, 2025 voteForm 8-K2025-05-150000950170-25-072817Item 5.07 · say-on-pay result. As reported: 71.09% (votes for as printed: 88,817,073). Filing ↗
60Section 06, 2024 voteForm 8-K2024-04-220000950170-24-046290Item 5.07 · say-on-pay result. As reported: 79.53% (votes for as printed: 111,449,588). Filing ↗
61Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
62Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
63Section 09b board cost (computed)ComputedcomputedCash 485,161 + equity 0 + all other 0 = 485,161, summed across the director compensation table rows.machine: formula: Σ = 485,161
64Evolus, Inc., Section 10b CEO totalDEF 14A2026-04-290001570562-26-000059CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. Filing ↗machine: span 499358–499367
65Amarin Corp PLC\UK (subject), Section 10b CEO totalDEF 14A2026-04-100001193125-26-151417CEO total compensation as printed in Amarin Corp PLC\UK's own proxy. As printed: 3,540,366. Filing ↗machine: r2 · c30 · span 991658–991667
66Esperion Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-160001628280-26-025499CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847
67Heron Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-196306CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221
68Section 10a, Evolus, Inc. reciprocityDEF 14A0001570562-26-000059Evolus, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC\UK. Filing ↗
69Section 10a, Heron Therapeutics, Inc. reciprocityDEF 14A0001193125-26-196306Heron Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC\UK. Filing ↗